Clinical Validation of Fragile X Syndrome Screening by DNA Methylation Array

Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability. It is most frequently caused by an abnormal expansion of the CGG trinucleotide repeat (>200 repeats) located in the promoter of the fragile X mental retardation gene (FMR1), resulting in promoter DNA hypermethylation and gene silencing. Current clinical tests for FXS are technically challenging and labor intensive, and may involve use of hazardous chemicals or radioisotopes. We clinically validated the Illumina Infinium HumanMethylation450 DNA methylation array for FXS screening.

http://jmd.amjpathol.org/article/S1525-1578(16)30133-7/fulltext?rss=yes

Source: Journal of Molecular Diagnostics - August 28, 2016 Category: Pathology Authors: Laila C. Schenkel, Charles Schwartz, Cindy Skinner, David Rodenhiser, Peter Ainsworth, Guillaume Pare, Bekim Sadikovic Tags: Technical Advance Source Type: research